CFL1 and lung adenocarcinoma: We validated the dose-dependent effect of LIMKi on inhibiting LIMK activity by treating A549 human lung adenocarcinoma epithelial cells for 18 hours with DMSO vehicle or 1, 3 or 10 μM LIMKi [9, 21] and western blotting for phosphorylation of cofilin, a well-characterized LIMK substrate [9] (Figure 1A).